We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Johnson & Johnson | LSE:0R34 | London | Ordinary Share | JOHNSON & JOHNSON ORD (CDI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| -1.30 | -0.87% | 148.60 | 144.80 | 152.40 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 9,827 | 16:35:05 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 85.16B | 35.15B | 14.6028 | 10.22 | 359.33B |
| Date | Time | Source | Headline |
|---|---|---|---|
| 01/5/2024 | 14:17 | ALNC |  TOP NEWS: J&J proposes USD6.48 billion settlement of cancer lawsuits |
| 16/4/2024 | 11:54 | ALNC | TOP NEWS: Johnson & Johnson upgrades guidance on swing to earnings |
| 05/4/2024 | 12:02 | ALNC | TOP NEWS: J&J swoops for Shockwave Medical in USD13.1 billion deal |
| 25/3/2024 | 18:28 | ALNC | IN BRIEF: J&J submits US premarket approval application for Varipulse |
| 18/3/2024 | 11:10 | ALNC | IN BRIEF: Johnson & Johnson receives FDA recommendation for Carvykti |
| 23/2/2024 | 18:32 | ALNC | IN BRIEF: Johnson & Johnson gets EMA nod for Carvykti in myeloma |
| 02/2/2024 | 06:22 | ALNC | TOP NEWS: US sends drugmakers initial offers in Medicare price talks |
| 23/1/2024 | 11:41 | ALNC | TOP NEWS: Johnson & Johnson eyes future growth; 2023 sales rise |
| 19/1/2024 | 21:34 | ALNC | IN BRIEF: J&J gets US FDA approval for cancer treatment Balversa |
| 05/12/2023 | 13:24 | ALNC | TOP NEWS: J&J expects strong long-term growth in three key drivers |
1 Year Johnson & Johnson Chart |
Intraday Johnson & Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
